Astrana Health Finalizes $675M Prospect Acquisition; Acquired Unit Reports Net Loss, High Liabilities
ASTH sits 35% above its 52-week low of $18.08.
Summary
Astrana Health has completed its $674.9 million acquisition of Prospect Health Plan, Alta Newport, and related assets, and has now provided interim unaudited financials for the acquired business. While the company's recent 10-K (March 12, 2026) referenced "strong revenue growth from a major acquisition," these new financials offer specific details. The acquired business reported a net loss of $38.7 million on $961.8 million in revenue for a nine-month period, alongside significant total liabilities of $1.57 billion. This acquisition is material, representing over 50% of Astrana Health's market capitalization, and the detailed financial performance of the acquired entity, particularly its net loss and substantial liabilities, provides a more nuanced view of the deal's impact. Traders will be assessing the implications of integrating these financially challenged assets into Astrana Health's overall operations and balance sheet.
At the time of this announcement, ASTH was trading at $24.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $18.08 to $34.80. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.